We are live on ! Find out more
TCM

Tybourne Capital Management Portfolio holdings

AUM $30.9M
1-Year Est. Return 20.1%
This Fund
S&P 500
This Quarter Est. Return
+26.69%
1 Year Est. Return
+20.1%
3 Year Est. Return
+108.99%
5 Year Est. Return
+80.28%
10 Year Est. Return
+751.59%
AUM
$34.5M
AUM Growth
+$11M
Cap. Flow
+$7.73M
Cap. Flow %
22.39%
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
4
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$6.61M
2
BCYC
Bicycle Therapeutics
BCYC
+$3.32M
3
MBUU icon
Malibu Boats
MBUU
+$2.01M
4
FBRX icon
Forte Biosciences
FBRX
+$1.43M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$858K

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 93.95%
2 Consumer Discretionary 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FBRX icon
1
Forte Biosciences
FBRX
$1.22B
$10.2M 29.45%
786,647
+166,666
+27% +$1.43M
TSHA icon
2
Taysha Gene Therapies
TSHA
$1.68B
$9.46M 27.39%
4,095,000
+395,000
+11% +$858K
BCYC
3
Bicycle Therapeutics
BCYC
$290M
$6.91M 20%
993,743
+417,400
+72% +$3.32M
ALMS
4
Alumis Inc
ALMS
$3.61B
$4.2M 12.15%
+1,399,250
New +$6.61M
MBUU icon
5
Malibu Boats
MBUU
$535M
$2.09M 6.05%
+66,705
New +$2.01M
ZNTL icon
6
Zentalis Pharmaceuticals
ZNTL
$317M
$1.71M 4.96%
1,478,152
+516,666
+54% +$681K
SLRN
7
DELISTED
ACELYRIN
SLRN
– –
-2,906,629
Closed -$7.18M

Similar funds

VM
Valinor Management New York $32.2M AUM 44.16% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
NC
Nucleo Capital Sao Paulo, Sp, Brazil $29.1M AUM 59.16% 1-Year Est. Return
PIM
Pinnacle Investment Management Hong Kong $28.9M AUM 32% 1-Year Est. Return
BCA
Burren Capital Advisors Gibraltar $33M AUM 47.67% 1-Year Est. Return
NCPI
NewView Capital Partners I Burlingame, California $28M AUM 10.55% 1-Year Est. Return
RE
ROB Exploration New York $27.3M AUM 13.99% 1-Year Est. Return
AECF
Annie E. Casey Foundation Baltimore, Maryland $35.2M AUM 35.05% 1-Year Est. Return

Tybourne Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Tybourne Capital Management held 7 positions worth $34.5M, up 47% from $23.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Tybourne Capital Management deployed $7.73M of net new capital in Q2 2025, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Alumis Inc: 1,399,250 shares worth $4.2M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier, followed by Consumer Discretionary.

On the sell side, the most notable exit was ACELYRIN, an estimated $7.18M sold.

  • Tybourne Capital Management's largest Q2 2025 buy was Alumis Inc: 1,399,250 shares worth $4.2M.
  • Tybourne Capital Management added most to Bicycle Therapeutics in Q2 2025, an estimated $3.32M increase.
  • Tybourne Capital Management fully exited ACELYRIN in Q2 2025, selling an estimated $7.18M.
  • Tybourne Capital Management's ten largest holdings make up 100% of its $34.5M portfolio in Q2 2025.
  • Tybourne Capital Management opened 2 new positions and closed 1 in Q2 2025.
  • Tybourne Capital Management's portfolio value rose 47% quarter-over-quarter to $34.5M.

Based on Tybourne Capital Management's 13F filing for Q2 2025, filed 1 Aug 2025.